Sotrovimab Expanded Access Treatment Protocol (COVID-19)
1 other identifier
expanded_access
N/A
1 country
4
Brief Summary
An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 13, 2022
CompletedFirst Posted
Study publicly available on registry
February 11, 2022
CompletedNovember 10, 2022
November 1, 2022
January 13, 2022
November 4, 2022
Conditions
Keywords
Interventions
500mg IV
Eligibility Criteria
You may qualify if:
- In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab
- patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria
You may not qualify if:
- Hospitalized due to COVID-19 (excludes nosocomial infection)
- Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Site
Palo Alto, California, 94304, United States
Site
Boston, Massachusetts, 02114, United States
Site
St Louis, Missouri, 63110, United States
Site
Seattle, Washington, 98109, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 13, 2022
First Posted
February 11, 2022
Last Updated
November 10, 2022
Record last verified: 2022-11